FDA panel endorses approval of Alzheimers drug shown to slow progression of disease WSB-TV Channel 2 [Video]

A panel of independent advisors to the U.S. Food and Drug Administration has recommended an experimental Alzheimer’s medication that has been shown to significantly slow the progression of mental decline in people with early symptomatic Alzheimer’s disease.

If approved by the FDA, Eli Lilly’s Alzheimer’s drug donanemab would become the second Alzheimer’s drug of its kind currently on the U.S. market that appears to retard the progression of the mind-wasting disease that 6 million Americans suffer from.

The other treatment on the market aimed at slowing Alzheimer’s is Leqembi from Biogen and Eisai.

The FDA typically follows the recommendations of its advisory panels but is not required to do so. The drug is likely to receive full approval in the U.S. later this year.

The 11 committee members unanimously said available data on the drug shows that it is effective at treating Alzheimer’s patients who are in the early stages …